The venous effects of nitric oxide donors and the phosphodiesterase type V inhibitor, Zaprinast
It is well-documented that agents which release nitric oxide (NO) or inhibit the degradation of cGMP promote vasodilatation by interacting with the endogenous Larginine/ NO pathway. There are few published in vivo studies examining the actions of these agents on the venous circulation. Although t...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
2009
|
| Online Access: | http://hdl.handle.net/2429/8192 |